Shilpa Biologicals has launched PartnerPower, a purpose-built digital transparency platform that empowers global sponsors with uninterrupted, real-time insights into every stage of their biologics development and manufacturing programs.

Engineered as a unified digital 'data fabric,' PartnerPower replaces traditional periodic reporting with a continuously live, collaborative environment—enabling biopharmaceutical innovators worldwide to monitor the true 'state of affairs' of their projects at any moment, from anywhere in the world. It delivers real-time visibility into process development laboratories and Good Manufacturing Practice (GMP) manufacturing environments, providing sponsors with direct access to operational data as it is generated.

By linking information across Research and Development (R&D), analytical development, and manufacturing operations, the platform is designed to support closer coordination, faster decision-making, and more efficient technology transfer.

The launch is another component of Shilpa Biologicals’ wider strategy to elevate the global Contract Development and Manufacturing Organisation (CDMO) experience from transactional outsourcing to a fully integrated, partnership-driven model.

The platform has also been designed with data integrity and sponsor confidentiality as core principles, and aligned with the expectations of global regulatory authorities—including the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and Pharmaceuticals and Medical Devices Agency (PMDA)—it enables a continuous state of audit readiness.

Madhav Bhutada, Director, Shilpa Biologicals, commented, “With PartnerPower, we are setting a new global benchmark for what transparency in a CDMO partnership should look like. It allows our sponsors to innovate with complete confidence, knowing that every data point, every decision, and milestone is visible to them in real time.”

The launch of PartnerPower adds to Shilpa Biologicals’ continued investment in world-class biologics capabilities, including its dedicated bioconjugation suites for Antibody Drug Conjugates (ADCs), one of the world’s largest microbial sites as well as a commercial mAbs facility.